Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether a mindful walking program is effective in the treatment of patients with chronic low back pain.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Mindful walking | Active Comparator | A weekly 60 minutes walking group exercise program consisting of a combination of walking and mindfulness over 8 weeks. |
|
| Waiting group | No Intervention |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Mindful walking program | Behavioral |
|
| Measure | Description | Time Frame |
|---|---|---|
| Pain intensity on visual analogue scale | 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Back function - FFbH-R-Questionnaire | 8 weeks, 12 weeks | |
| Pain intensity on visual analogue scale | 12 weeks | |
| Cohens perceived stress scale |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institute for Social Medicine, Epidemiology and Health Economics, Charité Universitätsmedizin Berlin, Germany | Berlin | State of Berlin | 10117 | Germany |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35363058 | Derived | Rotter G, Ortiz M, Binting S, Tomzik J, Reese F, Roll S, Brinkhaus B, Teut M. Mindful Walking in Patients with Chronic Low Back Pain: A Randomized Controlled Trial. J Integr Complement Med. 2022 Jun;28(6):474-483. doi: 10.1089/jicm.2021.0361. Epub 2022 Mar 30. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 8 weeks, 12 weeks |
| Quality of Life - SF 36 | 8 weeks, 12 weeks |
| Intake of paracetamol | 8 weeks |
| Adverse events | 8 weeks, 12 weeks |